Targeted Medical Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRGM research report →
Price Chart
About the company
Targeted Medical Pharma, Inc. , a specialty pharmaceutical company, doing business as Physician Therapeutics, develops and commercializes amino acid based medications to physicians, pharmacies, and patients in the United States. It offers a line of patented amino acid based medical food products, dietary supplements, and generic drugs primarily for the treatment of metabolic syndrome/obesity; sleep disorders associated with anxiety; hypertension; viral infections; cognitive disorders/fatigue; sleep disorders associated with depression, fibromyalgia, and PTSD; pain disorders and inflammatory conditions/fibromyalgia; osteoarthritis and joint disorders; and peripheral neuropathy.
- CEO
- Cameron Tymstra
- IPO
- 2012
- Employees
- 30
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on TRGM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $302
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -3.13
- Div Yield
- 0.00%
- Gross Margin
- 60.17%
- Op Margin
- -38.58%
- Net Margin
- -57.86%
- ROE
- 26.62%
- ROIC
- 26.62%
Latest fiscal year · YoY change
- Revenue
- $5.26M-26.0%
- Gross Profit
- $3.17M-35.3%
- Op Income
- $-2,029,773
- Net Income
- $-3,043,810+21.9%
- EPS
- $-0.11+26.7%
- OCF Growth
- -263.9%
- FCF Growth
- -263.9%
- 52W High
- $0.02
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.03
- RSI (14)
- 32
- Avg Volume
- 6.36K
No earnings-call transcripts are available for TRGM yet.
- Free Float
- 38.4%
- Shares Outstanding
- 30.19M
- Float Shares
- 11.58M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 4, 16 | DEWALD MAURICE J | other | 200,000 |
| Mar 4, 16 | DEWALD MAURICE J | other | 100,000 |
| Jul 22, 13 | Gottlieb Scott | other | 25,000 |
| Jul 22, 13 | Gottlieb Scott | other | 25,000 |
| Jul 22, 13 | Gottlieb Scott | other | 0 |
| Jul 22, 13 | DEWALD MAURICE J | other | 25,000 |
| Jul 22, 13 | DEWALD MAURICE J | other | 25,000 |
| Mar 1, 13 | DEWALD MAURICE J | other | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRGM coverage
Recent articles, reports, and earnings notes.
No research on TRGM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRGM report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.